Biodesix Inc (BDSX) - Total Assets
Based on the latest financial reports, Biodesix Inc (BDSX) holds total assets worth $94.64 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Biodesix Inc (BDSX) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Biodesix Inc - Total Assets Trend (2018–2025)
This chart illustrates how Biodesix Inc's total assets have evolved over time, based on quarterly financial data. See BDSX total equity for net asset value and shareholders' equity analysis.
Biodesix Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Biodesix Inc's total assets of $94.64 Million consist of 37.2% current assets and 62.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 21.7% |
| Accounts Receivable | $9.04 Million | 10.3% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $3.88 Million | 4.4% |
| Goodwill | $15.03 Million | 17.2% |
Asset Composition Trend (2018–2025)
This chart illustrates how Biodesix Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Biodesix Inc market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Biodesix Inc's current assets represent 37.2% of total assets in 2025, an increase from 25.4% in 2018.
- Cash Position: Cash and equivalents constituted 21.7% of total assets in 2025, up from 15.1% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 21.0% of total assets, a decrease from 70.0% in 2018.
- Asset Diversification: The largest asset category is goodwill at 17.2% of total assets.
Biodesix Inc Competitors by Total Assets
Key competitors of Biodesix Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Thyrocare Technologies Limited
NSE:THYROCARE
|
India | Rs7.47 Billion |
|
Shanghai Runda Med Tech Co
SHG:603108
|
China | CN¥13.79 Billion |
|
Integral Diagnostics Ltd
AU:IDX
|
Australia | AU$1.43 Billion |
|
Australian Clinical Labs Ltd
AU:ACL
|
Australia | AU$562.50 Million |
|
Shanghai Rendu Biotechnology Co. Ltd. A
SHG:688193
|
China | CN¥984.02 Million |
|
Monash Ivf Group Ltd
AU:MVF
|
Australia | AU$510.21 Million |
|
BioPorto
CO:BIOPOR
|
Denmark | Dkr93.18 Million |
|
RHYTHM Biosciences Ltd
AU:RHY
|
Australia | AU$3.10 Million |
Biodesix Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.82 | 2.22 | 3.22 |
| Quick Ratio | 2.82 | 2.22 | 3.07 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $26.42 Million | $16.31 Million | $47.18 Million |
Biodesix Inc - Advanced Valuation Insights
This section examines the relationship between Biodesix Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 24.96 |
| Latest Market Cap to Assets Ratio | 2.41 |
| Asset Growth Rate (YoY) | -10.0% |
| Total Assets | $87.48 Million |
| Market Capitalization | $210.64 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Biodesix Inc's assets at a significant premium (2.41x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Biodesix Inc's assets decreased by 10.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Biodesix Inc (2018–2025)
The table below shows the annual total assets of Biodesix Inc from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $87.48 Million | -10.04% |
| 2024-12-31 | $97.24 Million | -1.87% |
| 2023-12-31 | $99.10 Million | +6.66% |
| 2022-12-31 | $92.91 Million | +22.09% |
| 2021-12-31 | $76.10 Million | -37.15% |
| 2020-12-31 | $121.07 Million | +190.80% |
| 2019-12-31 | $41.63 Million | +6.60% |
| 2018-12-31 | $39.06 Million | -- |
About Biodesix Inc
Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also pro… Read more